NASDAQ:IPHA Innate Pharma Q4 2025 Earnings Results & Report $1.45 -0.02 (-1.36%) As of 10:41 AM Eastern This is a fair market value price provided by Massive. Learn more. Innate Pharma reported Q4 2025 earnings on February 14, 2026. The company reported EPS of -$0.18, while revenue was $2.41 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateFebruary 14, 2026TimeAfter Market Closes Innate Pharma EPS ResultsActual EPS-$0.18Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AInnate Pharma Revenue ResultsActual Revenue$2.41 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Innate Pharma Q4 2025 Earnings FAQ Did Innate Pharma beat earnings estimates for Q4 2025? Innate Pharma (NASDAQ:IPHA) reported earnings of -$0.18 per share for Q4 2025. The report was announced on Saturday, February 14, 2026. What was Innate Pharma's revenue for Q4 2025? Innate Pharma reported revenue of $2.41 million for Q4 2025. Innate Pharma Earnings HeadlinesInnate Pharma SA - Depositary receipt price target increased by 27.91% to $8.22October 2, 2026 | msn.comInnate Pharma (IPHA) Closes Sobi Deal. Can the New Funding Keep Drug Trials on Track?September 23, 2026 | finance.yahoo.comThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen no cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.October 14 at 1:00 AM | Behind the Markets (Ad)Analysts Offer Insights on Healthcare Companies: Innate Pharma (IPHA) and Alnylam Pharma (ALNY)September 22, 2026 | theglobeandmail.comInnate Pharma S.A. (IPHA) Q2 2026 Earnings Call TranscriptSeptember 17, 2026 | seekingalpha.comInnate Pharma Reports H1 Loss Narrows; Advances Lacutamab And IPH4502September 17, 2026 | rttnews.comSee More Innate Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Innate Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innate Pharma and other key companies, straight to your email. Email Address About Innate PharmaInnate Pharma (NASDAQ:IPHA) S.A. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is centered on the innate immune system, including natural killer cells and other immune cells that can recognize and attack tumors. Its product candidates include monoclonal antibodies, immune-cell engagers and other treatments designed to stimulate or direct immune responses against cancer. Innate Pharma’s pipeline has included lacutamab, an antibody targeting KIR3DL2 for the treatment of certain T-cell lymphomas, including cutaneous T-cell lymphoma. The company has also developed additional innate immune cell-engaging programs and has pursued research collaborations and licensing arrangements with larger pharmaceutical companies, including programs involving antibodies designed to activate natural killer cells. Founded in 1999 and headquartered in Marseille, France, Innate Pharma conducts research and clinical development activities in France and the United States and works with international pharmaceutical partners. The company is listed on Euronext Paris and its American depositary shares trade on the Nasdaq Global Select Market under the symbol IPHA.View Innate Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
